The market size of the Global Patient Recruitment and Retention Services Market in the year 2021 is valued at 3.63 billion and is predicted to reach 5.45 billion by the year 2030 at an 4.7% CAGR during the projected period.
Patient recruitment and retention is an essential service for the clinical research industry, and certain developments are expected to play a significant role in the future. Patient recruitment is one of the rate-limiting stages in bringing medications to market. In addition, given the typical clinical research dropout rate, keeping patients on board is challenging. Utilizing contract service providers has been shown to hasten the patient recruiting process. In order to effectively conduct clinical research, these service providers employ a variety of outreach strategies, such as social media, mobile technologies, electronic health records (EHRs), and real-world evidence (RWE). Over time, they have become increasingly significant in this process. Clinical research is conducted to learn more about the effectiveness and safety of creating new medications and medical equipment. As more people are needed for clinical trials because of regulatory and safety concerns, which are pushing trends toward longer and larger studies, the demand for patient recruiting services is increasing. The global industry has grown significantly as a result of the increasing number of clinical studies and the expanding pharmaceutical and medical industries.
With the increased complexity of clinical trials and the need for specialized patient populations for studies evaluating orphan medications and tailored therapies, several big pharma companies have outsourced their patient recruiting operations, leading to increased clinical trial costs. Delays in product release brought on by sponsors' inability to draw in and keep patients are relatively common and are considered to result in an average loss. The short suspension due to Covid-19 has significantly impacted clinical studies, especially in the area of patient recruiting.
The Patient Recruitment and Retention Services Market is segmented on the basis of Therapeutic Areas, Patient Recruitment Steps, and Trial Phases. Based on Therapeutic Areas, the market is segmented into Cardiovascular Diseases, Oncological Disorders, Infectious Diseases, CNS Disorders, Respiratory Disorders, Hematological Disorders, and Others. Based on Patient Recruitment Steps, the market is segmented into Pre-screening and Screening. Based on Trial Phases, the market is segmented into Phase I, Phase II, Phase III, and Phase IV.
Based on Therapeutic Areas, the oncology segment is accounted as a major contributor to the Patient Recruitment and Retention Services Market
The market for patient recruiting services linked to oncology is predicted to grow at a rapid pace over the forecast period. The upsurge in incidence and prevalence of various cancer disorders, the popularity of advanced therapies (such as biological and targeted pharmacological therapies), and the rising global elderly population are the main factors driving the growth of the oncology/cancer pharmaceuticals market. Additionally, the market for oncology medications is growing due to increased cancer awareness and early cancer detection. During the foreseeable period, profitable opportunities should be available due to the great potential of rising economies and the increased number of potential medications in development. The rate of advancement in cancer treatment is quickening. Emerging from the research and development pipeline are a number of novel therapies that are frequently combined with other brand-new or current medications. Numerous pharmaceutical companies are funding these revolutionary medication development projects for the treatment of cancer.
Based on Trial Phases, the phase III segment is accounted as a major contributor to the Patient Recruitment and Retention Services Market
The phase III category will lead the market in the forecast period with a major revenue share due to the high cost of phase III research. Complicated clinical trials need both clinical resources and potent technology for effective patient recruitment, timely deployment of trial locations, and high-quality study management. The vast majority of pharmaceutical, biopharmaceutical, and medical device companies worldwide use clinical trial service providers to conduct Phase III clinical trials. The market will expand as a result of the several medicines and vaccines that are currently in Phase III and are indicated for the treatment of COVID-19.
In the region, the North America Patient Recruitment and Retention Services Market holds a significant revenue share.
In 2021, North America had the greatest revenue share in the worldwide market. This market is projected to grow given the numerous clinical research being conducted in the region. Government support for clinical trials and significant R&D expenditures are fostering the market's growth. The presence of significant CROs offering support services like patient recruitment and multinational pharmaceutical and biopharmaceutical companies making sizable investments in clinical research have both been credited with the growth of the North American clinical trial patient recruitment services market. The region has become a hub for conducting clinical trials due to the low cost of research, straightforward regulatory compliance, rising patient population, and availability of a few elite clinical institutions functioning as sites.
The key players in the Patient Recruitment and Retention Services Market are Acurian, BBK Worldwide, Bright Pharmaceutical Services, ClinEdge, CSSi, CTM, Evolution Research Group (ERG), Integrated Clinical Trial Services (ICTS), MMG, Veristat, WCCT Global, Antidote, Clinical Accelerator, Fidelis Research, Ignite Data, Polaris BioPharma Consulting, Raremark, Clinrol, CROee, Gitzo Medical Technology, Pacific Grove, and TrialWire.